{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"49"}]}],"title":"Low CTX (<0.415ng/ml)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"54"}]}],"title":"High CTX (>.0.415ng/ml)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"103"}],"units":"Participants"}],"description":"To compare the suppression of serum markers of bone resorption of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing. The number of patients with high \\& low CTX values by arm will be reported here.","groups":[{"description":"Patients with Prostate Cancer receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Prostate Cancer 4 Weeks"},{"description":"Patients with Prostate Cancer receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Prostate Cancer 12 Weeks"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"207 prostate cancer patients who were treated and included in this portion of the substudy.","reportingStatus":"POSTED","timeFrame":"from baseline up to 24 months","title":"Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Prostate Cancer)","type":"SECONDARY","unitOfMeasure":"Participants"}